RE: RNS3 Mar 2016 09:11
Share consolidation is good for the long term future, but will likely open us up for dilution.
They have not yet started Phase 1 trials, so there will be significant funds needed to take this through to Phase 3 trials, which will take a long time. Is does state that Oxford University will arrange funding, but doesn't say how this will be achieved or whether this will negatively impact the % ownership of iOx Therapeutics, diluting shareholders.
Generally a good sector to be in as Big Pharma want to buy into the latest advancements. Cancer immunotherapy is where this is going long term.
Most treatments target specific cancel cells, and I cant see anything stating which type of cancer their treatment targets. If it's suitable for all then sounds like we could be on to a winner.
I was in here for a small punt before they changed to life sciences and am invested in another cancer immunotherapy company which is further along in the clinical process.
Definitely one to keep on the radar as we progress.